{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:19:12Z","timestamp":1795029552191,"version":"4.10.2"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32-CA78207"],"award-info":[{"award-number":["T32-CA78207"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.critrevonc.2024.104352","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T06:59:00Z","timestamp":1713250740000},"page":"104352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-2352","authenticated-orcid":false,"given":"Yu","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Karol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Reford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeh","family":"Izadmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah B.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2024.104352_bib1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clgc.2021.11.010","article-title":"Enhanced bellmunt risk score for survival prediction in urothelial carcinoma treated with immunotherapy","volume":"20","author":"Abuhelwa","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104352_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007765","article-title":"Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study","volume":"11","author":"Barth","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104352_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/onco.13727","article-title":"Baseline modified glasgow prognostic score associated with survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors","volume":"26","author":"Brown","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104352_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104352_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/07853890009011772","article-title":"Function of C-reactive protein","volume":"32","author":"Du Clos","year":"2000","journal-title":"Ann. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104352_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s12032-013-0705-6","article-title":"Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder","volume":"30","author":"Eggers","year":"2013","journal-title":"Med Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104352_bib7","article-title":"Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: a retrospective single-center analysis in Japan","volume":"4","author":"Fujiwara","year":"2021","journal-title":"Cancer Rep. (Hoboken)"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104352_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104352_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104352_bib10","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1515\/med-2021-0277","article-title":"Prognostic value of preoperative inflammation-based predictors in patients with bladder carcinoma after radical cystectomy","volume":"16","author":"Gui","year":"2021","journal-title":"Open Med (Wars. )"},{"key":"10.1016\/j.critrevonc.2024.104352_bib11","article-title":"The predictive potential of the baseline c-reactive protein levels for the efficiency of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis","volume":"13","author":"Han","year":"2022","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104352_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.bjc.6602406","article-title":"The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder","volume":"92","author":"Hilmy","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104352_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41571-020-00459-9","article-title":"Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?","volume":"18","author":"Hou","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104352_bib14","article-title":"CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104352_bib15","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/jjco\/hys124","article-title":"Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer","volume":"42","author":"Hwang","year":"2012","journal-title":"Jpn J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104352_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000531","article-title":"Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors","volume":"4","author":"Iivanainen","year":"2019","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104352_bib17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/bjc.2012.254","article-title":"Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis","volume":"107","author":"Ishioka","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104352_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejca.2022.02.022","article-title":"C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma","volume":"167","author":"Kl\u00fcmper","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104352_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/bjc.2014.631","article-title":"The prognostic value of pretreatment of systemic inflammatory responses in patients with urothelial carcinoma undergoing radical cystectomy","volume":"112","author":"Ku","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104352_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3892\/mco.2021.2216","article-title":"Postoperative C-reactive protein-to-albumin ratio predicts poor prognosis in patients with bladder cancer undergoing radial cystectomy","volume":"14","author":"Kuroda","year":"2021","journal-title":"Mol. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104352_bib21","first-page":"5799","article-title":"Prognostic value of preoperative systemic inflammatory responses in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor","volume":"10","author":"Mao","year":"2017","journal-title":"Int J. Clin. Exp. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104352_bib22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.eururo.2014.07.033","article-title":"Inflammatory biomarkers and bladder cancer prognosis: a systematic review","volume":"66","author":"Masson-Lecomte","year":"2014","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104352_bib23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.it.2014.12.008","article-title":"Versatile functions for IL-6 in metabolism and cancer","volume":"36","author":"Mauer","year":"2015","journal-title":"Trends Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104352_bib24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.urolonc.2016.05.013","article-title":"Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer","volume":"34","author":"Mbeutcha","year":"2016","journal-title":"Urol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104352_bib25","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10147-020-01690-1","article-title":"Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis","volume":"25","author":"Mori","year":"2020","journal-title":"Int J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104352_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.urolonc.2016.12.010","article-title":"Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder","volume":"35","author":"Nakagawa","year":"2017","journal-title":"Urol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104352_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/iju.13880","article-title":"Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy","volume":"26","author":"Nakata","year":"2019","journal-title":"Int J. Urol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104352_bib28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000525554","article-title":"Survival outcome after reduced-port laparoscopic radical cystectomy for bladder cancer: long-term follow-up analysis","volume":"100","author":"Noda","year":"2022","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104352_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246486","article-title":"C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients","volume":"16","author":"Patil","year":"2021","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104352_bib30","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J. Clin. Invest"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104352_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082319","article-title":"C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a Bi-center study","volume":"12","author":"Riedl","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104352_bib32","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s00345-020-03482-8","article-title":"Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy?","volume":"39","author":"Rodler","year":"2021","journal-title":"World J. Urol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104352_bib33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrurol.2011.145","article-title":"C-reactive protein as a biomarker for urological cancers","volume":"8","author":"Saito","year":"2011","journal-title":"Nat. Rev. Urol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104352_bib34","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1464-410X.2012.11153.x","article-title":"Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin","volume":"110","author":"Saito","year":"2012","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104352_bib35","doi-asserted-by":"crossref","first-page":"4.e7","DOI":"10.1016\/j.urolonc.2019.08.013","article-title":"Prognostic impact of tumor-associated immune cell infiltrates at radical cystectomy for bladder cancer","volume":"38","author":"Schubert","year":"2020","journal-title":"Urol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104352_bib36","article-title":"Clinical impact of sarcopenia and inflammatory\/nutritional markers in patients with unresectable metastatic urothelial carcinoma treated with pembrolizumab","volume":"10","author":"Shimizu","year":"2020","journal-title":"Diagn. (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104352_bib37","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/s41467-022-35096-6","article-title":"Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer","volume":"13","author":"Sui","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2024.104352_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/BLC-200354","article-title":"The controlling nutritional status (CONUT) score is a prognostic biomarker in advanced urothelial carcinoma patients treated with first-line platinum-based chemotherapy","volume":"7","author":"Suzuki","year":"2021","journal-title":"Bladder Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104352_bib39","doi-asserted-by":"crossref","first-page":"76.e11","DOI":"10.1016\/j.urolonc.2019.10.014","article-title":"Prognostic significance of the controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients","volume":"38","author":"Suzuki","year":"2020","journal-title":"Urol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104352_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urolonc.2018.11.002","article-title":"Prognostic significance of serum \u03b3-glutamyltransferase in patients with advanced urothelial carcinoma","volume":"37","author":"Takemura","year":"2019","journal-title":"Urol. Oncol."},{"issue":"7-8","key":"10.1016\/j.critrevonc.2024.104352_bib41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1159\/000506263","article-title":"Impact of routine laboratory parameters in patients undergoing radical cystectomy for urothelial carcinoma of the bladder: a long-term follow-up","volume":"104","author":"Tamalunas","year":"2020","journal-title":"Urol. Int"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104352_bib42","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10147-019-01613-9","article-title":"Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice","volume":"25","author":"Tamura","year":"2020","journal-title":"Int J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104352_bib43","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1159\/000521829","article-title":"Prognostic value of pretreatment inflammatory markers in patients receiving radical cystectomy for urothelial bladder cancer: does age matter?","volume":"106","author":"Volz","year":"2022","journal-title":"Urol. Int"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104352_bib44","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.21873\/anticanres.13539","article-title":"Initial experience of pembrolizumab therapy in japanese patients with metastatic urothelial cancer","volume":"39","author":"Yasuoka","year":"2019","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104352_bib45","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1464-410X.2007.07408.x","article-title":"C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy","volume":"101","author":"Yoshida","year":"2008","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104352_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000234","article-title":"C reactive protein impairs adaptive immunity in immune cells of patients with melanoma","volume":"8","author":"Yoshida","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104352_bib47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12881-019-0910-z","article-title":"Association of high sensitive C-reactive protein with coronary heart disease: a Mendelian randomization study","volume":"20","author":"Zhuang","year":"2019","journal-title":"BMC Med Genet"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T16:36:15Z","timestamp":1714408575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824000957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":47,"alternative-id":["S1040842824000957"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104352","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104352"}}